0001140361-22-044592.txt : 20221206 0001140361-22-044592.hdr.sgml : 20221206 20221206161951 ACCESSION NUMBER: 0001140361-22-044592 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20221206 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221206 DATE AS OF CHANGE: 20221206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC. CENTRAL INDEX KEY: 0001368514 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 562590442 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36728 FILM NUMBER: 221448028 BUSINESS ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 BUSINESS PHONE: (201) 478-5552 MAIL ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 FORMER COMPANY: FORMER CONFORMED NAME: R&R ACQUISITION VI, INC DATE OF NAME CHANGE: 20060707 8-K 1 ny20006122x2_8k.htm FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 6, 2022

ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
001-36728
56-2590442
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
   
465 State Route 17, Ramsey, New Jersey
07446
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (201) 478-5552

 
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
ADMA
Nasdaq Global Market

Item 2.02
Results of Operations and Financial Condition

On December 6, 2022, ADMA Biologics, Inc. (the “Company”) issued a press release announcing preliminary estimates for its total revenue for the quarter- and year-ended December 31, 2022. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01
Other Events

 Underwritten Equity Offering

On December 6, 2022, the Company issued a press release announcing that it has commenced an underwritten public offering of its common stock. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated into this Item 8.01 by reference.

Neither the disclosures on this Current Report on Form 8-K nor the exhibits hereto shall constitute an offer to sell or the solicitation of an offer to buy the securities described herein and therein, nor shall there be any sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Recent Developments

Morgan Stanley Strategic Alternatives Process Update

As an update to the Company’s strategic alternatives process, the Company continues to explore strategic alternatives with Morgan Stanley acting as its financial advisor, while also continuing to execute on its business plan of growing revenues, gross profit, improving profit margins and narrowing net losses on its pathway to profitability (forecasted for the first quarter of 2024).  During the ongoing strategic review process, the Company received several, non-binding acquisition offers, which the Company’s Board of Directors determined, in consultation with Morgan Stanley, did not provide sufficient value for the business, based on the Company’s strengthening fundamentals as a result of its continued execution.  The Company plans to continue to evaluate strategic alternatives with Morgan Stanley’s assistance and will entertain and evaluate inbound inquiries and opportunities.

Risk Factor Update

The following risk factor is provided to update and supplement the risk factors of the Company previously disclosed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022.


“To date, the Company has a history of losses and has historically needed to raise, and in the future may be required to raise, additional capital to operate its business.

Our long-term liquidity depends upon our ability to grow our commercial programs, expand our commercial operations at the Boca Facility, improve our supply-chain capabilities, improve production yields, provide more control and visibility for timing of commercial product releases, continue to build out our commercial infrastructure and meet our ongoing obligations. In addition, our end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months or potentially longer, requiring substantial investments in raw material plasma and other manufacturing materials.

The Company currently anticipates, based upon its projected revenue and expenditures, that its current cash, cash equivalents and accounts receivable, together with the estimated net proceeds of this offering, will be sufficient to fund its operations to cashflow positive, anticipated to be no later than the first quarter of 2024, at which time the Company believes it will begin to generate positive cash flow from operations. This time frame may change based upon how quickly the Company is able to execute on its commercialization efforts and operational initiatives and whether or not the assumptions underlying its projected revenues and expenses are correct. The Company anticipates that it will not be able to generate a sufficient amount of product revenue to achieve profitability until the beginning of 2024. If the Company is unable to raise additional capital if needed, it may have to delay, curtail or eliminate its commercialization efforts as well as product development activities. Even if the Company is able to raise additional capital, such equity or debt financings may only be available on unattractive terms, resulting in significant dilution of stockholders’ interests and, in such event, the value and potential future market price of our common stock may decline. In addition, if the Company raises additional funds through license arrangements or through the disposition of any of its assets, it may be necessary to relinquish potentially valuable rights to its product candidates or assets or grant licenses on terms that are not favorable to the Company.

The Company also continues to evaluate a variety of strategic alternatives through its ongoing engagement with Morgan Stanley. The Company will communicate material developments as required by the SEC. The exploration of value-creating opportunities remains a top corporate priority for ADMA.

Historically, the major source of the Company’s cash has been from proceeds from various public offerings of its common stock and the issuance of debt securities. The actual amount of cash that the Company will need is subject to many factors. There can be no assurances that additional financing will be available if needed or that management will be able to obtain financing on terms acceptable to the Company or that the Company will become profitable and generate positive operating cash flow.”

Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about the Company. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about the Company’s preliminary financial updates for the quarter- and year-ended December 31, 2022 and discussions about the underwritten public offering. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, the Company does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause the Company’s actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.


 
Item 9.01
Exhibits.

(d) Exhibits

Exhibit No.
Description

Press Release, dated December 6, 2022
99.2
 Press Release, dated December 6, 2022
104
Cover Page Interactive Data File (embedded with the Inline XBRL document)


 SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

December 6, 2022
ADMA Biologics, Inc.
   
 
By:
/s/ Brian Lenz
   
Name:
Brian Lenz
   
Title:
Executive Vice President and Chief Financial Officer

EX-99.1 2 ny20006122x2_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1


ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate

Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million

RAMSEY, N.J. and BOCA RATON, FL, December 6, 2022 - ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced preliminary estimates for its total revenue for the quarter- and year-ended December 31, 2022.

Based on the most current information available to ADMA’s management, including quarter-to-date performance, ADMA preliminarily estimates that its total revenue for the quarter- and year-ended December 31, 2022 will be between $48 million and $50 million and $152 million and $154 million, respectively. This forecasted fourth quarter 2022 revenue represents more than 85% year-over-year growth when compared to $26.4 million of total revenues for the fourth quarter of 2021.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 and European Patent No. 3375789, among others, related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include statements about the Company’s estimated fourth quarter and full-year 2022 total revenue. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.

COMPANY CONTACT:

Skyler Bloom
Senior Director, Corporate Strategy and Business Development | 201-478-5552 | sbloom@admabio.com

INVESTOR RELATIONS CONTACT:

Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com
EX-99.2 3 ny20006122x2_ex99-2.htm EXHIBIT 99.2
Exhibit 99.2


ADMA Biologics Announces Proposed Public Offering of Common Stock

RAMSEY, N.J. and BOCA RATON, FL, December 6, 2022 - ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

ADMA intends to use the net proceeds from this offering to accelerate commercialization and production activities, complete plasma center buildout and obtain FDA approvals, to conclude post FDA marketing approval research and development projects, and for working capital, capital expenditures and for general corporate purposes.

Raymond James & Associates, Inc., Cantor Fitzgerald & Co. and Mizuho Securities USA LLC are acting as joint book-running managers of the proposed offering.

The securities described above are being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-256643) previously filed with the Securities and Exchange Commission (“SEC”) and declared effective by the SEC on August 3, 2021. The preliminary prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, or by telephone at (800) 248-8863, or e-mail at prospectus@raymondjames.com, or from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022 or by email at prospectus@cantor.com, or from Mizuho Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd Floor, New York, NY 10020, by email at US-ECM@us.mizuho-sc.com, or by telephone at (212) 205-7600.

Before investing in the offering, you should read in their entirety the preliminary prospectus supplement and its accompanying prospectus to be filed with the SEC, and the other documents that the Company has filed with the SEC that will be incorporated by reference in the prospectus supplement and its accompanying prospectus, which will provide more information about the Company and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 and European Patent No. 3375789, among others, related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include statements about the offering, ADMA’s intention to grant the underwriters a 30-day option to purchase additional shares in the offering, and ADMA’s intended use of proceeds generated from the offering. Actual events or results may differ materially from those described in this document due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering and the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.

COMPANY CONTACT:

Skyler Bloom
Senior Director, Corporate Strategy and Business Development | 201-478-5552 | sbloom@admabio.com

INVESTOR RELATIONS CONTACT:

Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com
EX-101.SCH 4 adma-20221206.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 adma-20221206_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 6 adma-20221206_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 ny20006122x2_ex99-1image01.jpg begin 644 ny20006122x2_ex99-1image01.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Dec. 06, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 06, 2022
Entity File Number 001-36728
Entity Registrant Name ADMA BIOLOGICS, INC.
Entity Central Index Key 0001368514
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 56-2590442
Entity Address, Address Line One 465 State Route 17
Entity Address, City or Town Ramsey
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07446
City Area Code 201
Local Phone Number 478-5552
Title of 12(b) Security Common Stock
Trading Symbol ADMA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 9 ny20006122x2_8k_htm.xml IDEA: XBRL DOCUMENT 0001368514 2022-12-06 2022-12-06 false 0001368514 8-K 2022-12-06 ADMA BIOLOGICS, INC. DE 001-36728 56-2590442 465 State Route 17 Ramsey NJ 07446 201 478-5552 false false false false false Common Stock ADMA NASDAQ EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( '6"AE4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !U@H95KNUB@NX K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>*':@4)/FTM%3!X,5-G8SMMJ:Q7^P-9*^_9*L31G; ^QHZ>=/ MGT"-CE*'A,\I1$QD,3\,KO-9ZKAA9Z(H ;(^HU.Y'!-^;!Y#A:^ .F&"$R>7O IJ%.%?_Q,X=8-?DD.V2ZON^[.LY-^[ X>UI_S*O6UB? M27F-XZ]L)5TB;MAM\FN]?3SL6"LJ(0HNBFIU$%SRM:S7[Y/K#[^[L O&'NT_ M-KX)M@W\NHOV"U!+ P04 " !U@H95F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M '6"AE4EO#4D000 '@0 8 >&PO=V]R:W-H965T&UL MG9C;;N,V$(9?A5"!10O$T2'R(:EMP'&2K;LY>..T"[3H!2V-;2*2J))TG+Q] MA[(C>;/RR.A-+$J:7Y^&HW_(]#=2/>L5@&&O:9+I@;,R)K]P71VM(.7Z5.:0 MX96%5"DW.%1+5^<*>%P$I8D;>%['3;G(G&&_.#=5P[Y\(=]G.^A!F8/_*IPI%;JL0BA4P+F3$%BX$S\B\N@] & M%'?\*6"C]XZ9?96YE,]V,(D'CF>)(('(6 F./R\PAB2Q2LCQ[T[4*9]I _>/ MW]5OBI?'EYES#6.9?!.Q60V&X8. MB];:R'07C 2IR+:__'67B+V P#\0$.P"@H)[^Z""\HH;/NPKN6'*WHUJ]J!X MU2(:X41F9V5F%%X5&&>&5S):8Y(-XUG,KC,CS!N;9-O9QJSU78,/L;>ZT4[P M$'P?;B+;"5@4 (&A=[9 ;VQ? '%_A[-M5$XA?_4$6T5 MPGH%6]<7.N<1#!PL7 WJ!9SAIY_\CO*"XB;ARSH*.G[!$PT$1[OD:!^7C"DH(6U!Q0S+LC8O#4JVC(HZ M:BJD3LG6(15WQ7TC$F#WZW0.JHZ*UO \OW76Z08]@J=;\G2/X7F$I;"EC4F[ MYVEMIFB=T=7=B%U.'FX?/D_&LQ,VN1^?$GB]$J]W#-X89U/Q!#TAAE?V!=[J M &DE#[-VUNFU_9# .B^QSH_!FF215+E4A4F=L)G!(F-2L;%<(R]BR[@VE;3X MU35!Z'N5I7K',#[Q5S:),7]B(:("E*B[!LEVIQ6TS[TPI+X$?\_T_6,(1W&, MAJA/W@_8+=[''K+:U#5(AIWV;AH>L?D#\[L4:>7^/FG>/Y".[0@G^DENZIL3 M+??(4_VQAK\GJWS?IYW[(UE9@U,E7T06U2>1UKS_G4*KNH%/V_E'M*G4!K_A MOT1^\,-H4/2Z8=BAV*H.X=/&7DS@"!>0AU%H@<#S*9"J'?BTE]_*"',R7@KM4*M##\XRO"O4U!+FZ7/J&!66.!ISK/:^6L0;%J/!973![0M M?\-<&<@L2[K.=GU(UR+10HU(>PMZVH-G,A&1,#91=VB92O#:@FI0:>2IC#R@ M37>JH!5A>@ ]>[N2Q\4T[CD>%HMZ3VC0:R2K?#R@7?<'LHG6:R1K!/R?JWUW M;Q]I]^1WW-:S9@DL4,@[[:(SJ^TV=SLP,B^VEG-I<*-:'*Z (YN] :\OI#3O M [M;+?_9,/P/4$L#!!0 ( '6"AE6?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8 M^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L M*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @: ML!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI M\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6; M_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2 M]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$= MV_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M> M;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:* M(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D M>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8 MJ;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( '6"AE67BKL

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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://admabiologics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ny20006122x2_8k.htm adma-20221206.xsd adma-20221206_lab.xml adma-20221206_pre.xml ny20006122x2_ex99-1.htm ny20006122x2_ex99-2.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ny20006122x2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ny20006122x2_8k.htm" ] }, "labelLink": { "local": [ "adma-20221206_lab.xml" ] }, "presentationLink": { "local": [ "adma-20221206_pre.xml" ] }, "schema": { "local": [ "adma-20221206.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "adma", "nsuri": "http://admabiologics.com/20221206", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ny20006122x2_8k.htm", "contextRef": "c20221206to20221206", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://admabiologics.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ny20006122x2_8k.htm", "contextRef": "c20221206to20221206", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001140361-22-044592-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-044592-xbrl.zip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end